Gemtuzumab ozogamicin (MylotargTM is infrequently associated with sinusoidal obstruction sydrome

被引：0
|
作者：
Nabhan, C
Rundhaugen, LM
Riley, MB
Peterson, LC
Boehlke, LL
Poisson, BP
Tallman, MS
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol & Oncol, Chicago, IL 60611 USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4609
引用
收藏
页码：270B / 270B
页数：1
相关论文
共 50 条
  • [1] Gemtuzumab ozogamicin (Mylotarg™) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease
    Nabhan, C
    Rundhaugen, L
    Jatoi, M
    Riley, MB
    Boehlke, L
    Peterson, LC
    Tallman, MS
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (08) : 1231 - 1236
  • [2] Hepatic sinusoidal obstruction following Gemtuzumab Ozogamicin (Mylotarg™).
    Rajvanshi, P
    Shulman, HM
    Sievers, EL
    McDonald, GB
    [J]. HEPATOLOGY, 2001, 34 (04) : 452A - 452A
  • [3] Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotug) therapy
    Rajvanshi, P
    Shulman, HM
    Sievers, EL
    McDonald, GB
    [J]. BLOOD, 2002, 99 (07) : 2310 - 2314
  • [4] Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg®)
    McDonald, GB
    [J]. CLINICAL LYMPHOMA, 2002, 2 : S35 - S39
  • [5] MylotargTM (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
    Giles, FJ
    Kantarjian, HM
    Kornblau, SM
    Thomas, DA
    Garcia-Manero, G
    Waddelow, TA
    David, CL
    Phan, AT
    Colburn, DE
    Rashid, A
    Estey, EH
    [J]. CANCER, 2001, 92 (02) : 406 - 413
  • [6] Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy (vol 99, pg 2310, 2002)
    Rajvanshi
    [J]. BLOOD, 2002, 99 (11) : 3915 - 3915
  • [7] Gemtuzumab ozogamicin associated with liver injury
    [J]. Reactions Weekly, 2002, 903 (1) : 4 - 4
  • [8] Sinusoidal obstruction syndrome in allogeneic hematopoietic stem cell transplantation after prior Gemtuzumab Ozogamicin treatment: an EBMT retrospective survey
    Battipaglia, G.
    Labopin, M.
    Candoni, A.
    Fanin, R.
    El Cheikh, J.
    Blaise, D.
    Michallet, M.
    Ruggeri, A.
    Contentin, N.
    Ribera, J. M.
    Stadler, M.
    Sierra, J.
    von dem Borne, P. A.
    Adrien, B.
    Socie, G.
    Mohty, M.
    Nagler, A.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S78 - S79
  • [9] Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice
    Tallman, Martin S.
    McDonald, George B.
    DeLeve, Laurie D.
    Baer, Maria R.
    Cook, Michael N.
    Graepel, G. Jay
    Kollmer, Carl
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (04) : 456 - 464
  • [10] Incidence of Sinusoidal Obstruction Syndrome Following Mylotarg (Gemtuzumab Ozogamicin, GO): a Prospective Observational Study in Routine Clinical Practice.
    Tallman, Martin S.
    McDonald, George B.
    DeLeve, Laurie D.
    Obi-Tabot, Eliot
    Kollmer, Carl
    Feingold, Jay M.
    [J]. BLOOD, 2008, 112 (11) : 352 - 352
12345